INIFY Laboratories

INIFY Laboratories EBITDA per Share

The EBITDA per Share of INIFY Laboratories (INIFY.OL) as of Oct 28, 2026 is -0.87 SEK. In the previous year, EBITDA per Share was -1.05 SEK — a change of -17.43% (higher).

EBITDA per Share

-0.87SEK

YoY

-17.43%

Last updated:

EBITDA per Share of INIFY Laboratories is 2025 -0.87 SEK. EBITDA per Share of INIFY Laboratories was 2024 -1.05 SEK. It decreases by -17.43% higher compared to the previous year.

The INIFY Laboratories EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2023
-1.12 SEK
Jan 1, 2024
-1.05 SEK
Jan 1, 2025
-0.87 SEK
The INIFY Laboratories EBITDA per Share history
YEAREBITDA per ShareYoY
-0.87SEK-17.43%
-1.05SEK-5.72%
-1.12SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INIFY Laboratories Stock analysis

What does INIFY Laboratories do? INIFY Laboratories AB generates revenue through providing cancer diagnostics via digital pathology services. The company offers two primary services: Full pathology Reports signed by INIFY's subspecialized pathologists and Whole Slide Images (WSI) with Pathology Decision Support Tool (PDST) analysis results. These services target healthcare providers and institutions requiring efficient, AI-optimized diagnostics for prostate biopsies. The firm's Solna, Sweden laboratory handles the entire sample processing chain, from logistics to reporting, leveraging AI to enhance quality and speed. INIFY's workflow is fully digital and standardized, initially focusing on prostate diagnostics. The company's service model includes both direct reporting by INIFY pathologists and WSI generation with PDST analysis, catering to clients seeking streamlined pathology solutions. This approach differentiates INIFY from traditional pathology services by integrating AI support throughout the diagnostic process. The business originates from ContextVision, indicating a foundation in digital pathology innovation. INIFY's offerings are designed to optimize response times and quality in prostate biopsy analysis, serving healthcare organizations that require advanced diagnostic tools without managing the full pathology workflow internally. INIFY Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about INIFY Laboratories stock

EBITDA per Share of INIFY Laboratories is -0.87 SEK in 2025.

EBITDA per Share of INIFY Laboratories changed from -1.05 SEK to -0.87 SEK, representing a -17.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share INIFY Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — INIFY Laboratories

All Key Metrics — INIFY Laboratories